The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia

The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia - Coenzyme Q10 for dementia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019587

Enrollment

100

Registered

2015-11-01

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Demenita

Interventions

Dosement of rcoenzyme Q10 300mg per a day and other anti-dementia drugs for 12 months. Dosement of placebo per a day and other anti-dementia drugs for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: mild and moderate dementia

Exclusion criteria

Exclusion criteria: Head trauma, Drug abuse, Alcoholism, Schizophrenia

Design outcomes

Primary

Measure	Time frame
ADAS-J cog (Term for evaluation:onset, 6 months,12 months)	—

Secondary

Measure	Time frame
Neuropsychological Battery	—

Countries

Japan

Contacts

Public ContactMarina Ikeda

Shimane University Hospital Department of Neurology

cos3571@med.shimane-u.ac.jp0853-20-2199

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026